Anti-LAG-3 antibody LBL-007 plus anti-PD-1 antibody toripalimab in advanced nasopharyngeal carcinoma and other solid tumors: an open-label, multicenter, phase Ib/II trial - Chen, Gang; Sun, Dong-Chen; Ba, Yi; Zhang, Ya-Xiong; Zhou, Ting; Zhao, Yuan-Yuan; Zhao, Hong-Yun; Fang, Wen-Feng; Huang, Yan; Wang, Zhen; Deng, Chao; Hu, De-Sheng; et al. (Journal of hematology and oncology, 2025)
Keywords: Adult; Adverse events; Aged; Alanine transaminase; Antibodies; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - therapeutic use; Antigens, CD - immunology; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Antitumor activity; Aspartate; Aspartate aminotransferase; Biomarkers; Cancer; Carcinoma; CD223 antigen; Combination therapy; Consent; Disease control; Esophageal cancer; FDA approval; Female; Humans; Hyponatremia; Immune Checkpoint Inhibitors - adverse effects; Immune Checkpoint Inhibitors - therapeutic use; Immunotherapy; Lung cancer; Lymphocyte Activation Gene 3 Protein; Lymphocytes; Male; Medical research; Medicine, Experimental; Melanoma; Middle Aged; Nasopharyngeal carcinoma; Nasopharyngeal Carcinoma - drug therapy; Nasopharyngeal Carcinoma - pathology; Nasopharyngeal Neoplasms - drug therapy; Neoplasms - drug therapy; Patients; PD-1 protein; PD-L1 protein; Product development; Programmed Cell Death 1 Receptor - antagonists & inhibitors; Solid tumors; Squamous cell carcinoma; Toxicity; Tumors; Viral antibodies